Literature DB >> 19410195

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.

Hilde Brems1, Eline Beert, Thomy de Ravel, Eric Legius.   

Abstract

Neurofibromatosis type 1 (NF1) is a familial tumour syndrome. Malignant tumours can arise in the nervous and non-nervous system in either childhood or adulthood, with malignant peripheral nerve sheath tumours being most common. Rhabdomyosarcoma and neuroblastoma are paediatric neoplasms that are more common in children with NF1 than in those without the syndrome. Gastrointestinal stromal tumours, somatostatinomas, breast cancer, and phaeochromocytomas are seen in adults with NF1. Several pathways are thought to be involved in the development of tumours associated with NF1: rat sarcoma viral oncogene homologue (RAS)-mitogen activated protein kinase (MAPK), mammalian target of rapamycin (mTOR), and P21 protein (Cdc42/Rac)-activated kinase 1 (PAK1). New insights into the pathogenesis of these tumours will lead to a better understanding of tumour origin and development and will hopefully allow the discovery of new and specific treatments.

Entities:  

Mesh:

Year:  2009        PMID: 19410195     DOI: 10.1016/S1470-2045(09)70033-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  116 in total

1.  [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Authors:  L L Tsai; L Drubach; F Fahey; M Irons; S Voss; N J Ullrich
Journal:  J Neurooncol       Date:  2012-03-11       Impact factor: 4.130

2.  Relevance of MPNST cell lines as models for NF1 associated-tumors.

Authors:  Eric Pasmant; Armelle Luscan; Jennifer Varin; Ingrid Laurendeau; Béatrice Parfait; Dominique Vidaud
Journal:  J Neurooncol       Date:  2013-06-27       Impact factor: 4.130

Review 3.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

4.  Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform Neurofibromas In Vitro.

Authors:  Ziang Zou; Linna Guo; Victor Mautner; Ralf Smeets; Lan Kiuwe; Reinhard E Friedrich
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

5.  Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.

Authors:  Ye Won Jeon; Ra Mi Kim; Seung Taek Lim; Hyun Joo Choi; Young Jin Suh
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

Review 6.  Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.

Authors:  Anish Ray; Winston W Huh
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

7.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

8.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

Review 9.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

10.  Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Authors:  Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.